Delving into the Latest Updates on SARS-CoV-2 vaccine(Vicebio) with Synapse

Overview

Basic Info

Drug Type

Prophylactic vaccine

Synonyms-

Target-

Mechanism-

Therapeutic Areas

Infectious DiseasesRespiratory Diseases

Active Indication

COVID-19

Inactive Indication-

Originator Organization

Vicebio Ltd.

Active Organization

Vicebio Ltd.

Inactive Organization-

Drug Highest PhaseClinical

First Approval Date-

Regulation-

A review.Despite three doses of Severe Acute Respiratory Syndrome coro- navirus 2 (SARS-CoV-2) vaccine, the humoral response and con- sequently the clin. protection remain low in immunosuppressed patients, particularly in solid-organ-transplant patients.Casirivimabandimdevimabmonoclonalantibodieshadtobegiven monthly independently of the anti-S concentration, although it was mandatorytobemeasuredjustbeforeeachinfusion.Imunosuppressedpatientswithouthumoralresponsetofull vaccination.

100 Deals associated with SARS-CoV-2 vaccine(Vicebio)

Login to view more data